Rare disease drug varieties approved

STO-REC-STATNAEE4RT1 Official
39

China · 2024

Rare disease drug varieties approved in China stood at 39 in 2024 (State Council).

Original source
Publisher
State Council
Authority tier
T1 Official
Locator
更好满足临床急需
Retrieved
17 Sep 2026
Status
Verified

What the source says

不只注射用利纳西普,据罕见病信息网统计,全年批准罕见病用药39个品种,覆盖了34种罕见病。

Verbatim extraction verified: The figure 39 is directly attested in the quoted passage (更好满足临床急需).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
State Council of China. (2024). 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202501/content_6997982.htm. Via StatOrigin, https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R
MLA
State Council of China. "全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网." 2024, https://www.gov.cn/zhengce/202501/content_6997982.htm. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R.
Chicago
State Council of China. "全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网." 2024. https://www.gov.cn/zhengce/202501/content_6997982.htm. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R.
BibTeX
@misc{statecouncil2024rare1ms13r, author = {{State Council of China}}, title = {全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市\_政策解读\_中国政府网}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R}, note = {Original source: https://www.gov.cn/zhengce/202501/content\_6997982.htm. Accessed September 17, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATNAEE4R T1 Official

Primary Source

Publisher
State Council of China · homepage ↗
Authority tier
Tier 1 · Multilateral Official
Report
全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网
Type
Press release
Published
Locator
更好满足临床急需
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R